Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Arocell AB is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners but are both located within 1 distinct art unit, indicating a concentrated technical focus despite the involvement of multiple reviewers. This arrangement suggests that the company's current legal challenges are being addressed by a single specialized group at the patent office, even though the individual examiners differ.
FONTAINHAS, AURORA M is the busiest examiner, currently overseeing 1 pending office action. With 2 pending office actions and 2 distinct examiners, each examiner is responsible for 1 action. The fact that both examiners operate within 1 distinct art unit suggests that the company's current patent strategy is focused on a single technical domain. Practitioners should look for commonalities in how the 1 distinct art unit handles these 2 pending office actions, as the shared administrative environment may lead to similar examination patterns across the different examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONTAINHAS, AURORA M | 1 | 37.9% | +49.2% |
| DUNN, MCKENZIE A | 1 | 53.8% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572370 | PREDICTING CANCER RELAPSE | FONTAINHAS, AURORA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572370 | PREDICTING CANCER RELAPSE | FONTAINHAS, AURORA M | — |
| 17794286 | PREDICTING PATIENT SURVIVAL | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572370 | PREDICTING CANCER RELAPSE | FONTAINHAS, AURORA M | — | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 17794286 | PREDICTING PATIENT SURVIVAL | DUNN, MCKENZIE A | 1678 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial